INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nidec Corporation - NJDCY

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Nidec Corporation (“Nidec” or the “Company”) (OTCMKTS: NJDCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Nidec and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 3, 2025, Nidec disclosed that it had established a third-party committee to investigate suspicions of improper accounting.  The Company further revealed that its “investigations found multiple documents suggesting that . . . the Company and its group companies could have engaged in improper accounting with the involvement or knowledge of its or their management[.]” 

On this news, Nidec’s American Depositary Receipt (“ADR”) price fell $0.81 per ADR, or 16.5%, to close at $4.11 per ADR on September 4, 2025. 

Then, on September 26, 2025, Nidec disclosed further investigative findings of additional suspected inappropriate accounting practices, including “cases where the reported value for customs purposes was declared to be lower than the appropriate amount without legitimate reason.”  Nidec also revealed that it “received an audit report containing a disclaimer of opinion” from its auditor due to the “ongoing investigations by the third-party committee, other internal investigations, and other action[s].” 

On this news, Nidec’s ADR price fell $0.29 per share, or 6.6%, to close at $4.09 per ADR on September 26, 2025. 

On October 23, 2025, Nidec published a press release announcing that it was withdrawing its year-end forecast and had decided not to pay a surplus dividend, as “investigations by the Third Party Committee regarding suspected inappropriate accounting practices involving the Company and its group, as well as other internal investigations, are ongoing.” 

On this news, Nidec’s ADR price fell $1.17 per ADR, or 25.4%, to close at $3.43 per ADR on October 23, 2025. 

Finally, on October 27, 2025, the Tokyo Stock Exchange (“TSE”) designated Nidec under a Special Security alert in part because “TSE deems that the improvement of the internal management system of [Nidec] is highly necessary.”  The alert noted that “[s]ince the initial issue was discovered, the scope of the investigation has continued to expand” and that “deficiencies have already been identified in the Company’s company-wide internal control systems (particularly in areas related to information and communication), as well as in the internal controls related to its accounting and financial closing processes.” 

On this news, Nidec’s ADR price fell $0.80 per ADR, or 20.3%, to close at $3.15 per ADR on October 27, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Bradley, Inc. - VRA

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Vera Bradley, Inc. (“Vera Bradley” or the “Company”) (NASDAQ: VRA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Vera Bradley and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On June 11, 2025, Vera Bradley announced its financial results for the first quarter of fiscal year 2026.  The Company’s Chief Executive Officer described the results as “disappointing as top line and profitability trends from the previous several quarters continued.” 

On this news, Vera Bradley’s stock price fell $0.45 per share, or 19.15%, to close at $1.90 per share on June 11, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  AVITA Medical, Inc. (“AVITA” or the “Company”) (NASDAQ: RCEL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether AVITA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 16, 2025, AVITA issued a press release announcing that, effective immediately, “Jim Corbett is leaving his positions as CEO and member of the Board.” 

On this news, AVITA’s stock price fell $1.39 per share, or 25.84%, to close at $3.99 per share on October 17, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Coty, Inc. - COTY

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Coty, Inc. (“Coty” or the “Company”) (NYSE: COTY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Coty and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 20, 2025, Coty reported its financial results for its fourth quarter and full fiscal year 2025.  On a related earnings call, Coty’s Chief Financial Officer said that “[t]he challenges of fiscal year 2025 coincided with moderating profit in the broader beauty market,” attributing sluggish sales to factors ranging from value-seeking behavior, innovation fatigue by consumers, and anti-theft and immigration policy changes. 

On this news, Coty’s stock price fell $1.05 per share, or 21.6%, to close at $3.82 per share on August 21, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enphase Energy, Inc. - ENPH

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Enphase Energy, Inc. (“Enphase” or the “Company”) (NASDAQ: ENPH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Enphase and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 28, 2025, Enphase reported its financial results for the third quarter of 2025 and held a related earnings call.  Among other items, Enphase’s management reported that it expects 2025 to close on a weak note, with elevated channel inventory resulting in lower battery storage shipments in the fourth quarter, and that expiration of the residential solar investment tax credit would negatively impact revenues for the first quarter of 2026. 

On this news, Enphase’s stock price fell $5.56 per share, or 15.15%, to close at $31.14 per share on October 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stride, Inc. - LRN

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Stride and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 28, 2025, Stride issued a press release reporting its financial results for the first quarter of fiscal year 2026 ended September 30, 2025.  On a related earnings call that same day, Stride’s management disclosed that its 2026 sales growth projections were impacted by major issues in implementing an upgraded version of its online platform over the summer.  Stride’s Chief Executive Officer said that “[t]he implementations did not go as smoothly as we anticipated” and that “poor customer experience has resulted in some higher withdrawal and lower conversion rates than we expected.” 

On this news, Stride’s stock price fell $83.48 per share, or 54.37%, to close at $70.05 per share on October 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Camping World Holdings, Inc. - CWH

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Camping World Holdings, Inc. (“Camping World” or the “Company”) (NYSE: CWH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Camping World and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 28, 2025, Camping World issued a press release announcing its financial results for the third quarter of 2025.  Among other items, the press release disclosed that “the Company’s management identified prior period misstatements related to the measurement of the realizable portion of the Company’s outside basis difference deferred tax asset in CWGS Enterprises, LLC[.]”  Accordingly, Camping World revised its 2024 annual report, increasing its reported deferred tax assets by $43.8 million. 

On this news, Camping World’s stock price fell $4.17 per share, or 24.79%, to close at $12.65 per share on October 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Hormel Foods Corporation - HRL

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Hormel Foods Corporation (“Hormel” or the “Company”) (NYSE: HRL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Hormel and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 29, 2025, Hormel issued a press release announcing the departure of Chief Financial Officer Jacinth Smiley and “provid[ing] an update on several topics related to its fiscal 2025 fourth quarter, which ended on October 26, 2025.”  Hormel advised, among other things, that “the Company continued to experience persistent inflation in key commodity inputs, at levels exceeding expectations” and was “impacted by the spread of highly pathogenic avian influenza (HPAI) and pneumoviruses within the poultry industry.”  Hormel also said that “on October 25, 2025, the Company issued a voluntary, class 1 recall related to certain chicken products sold in foodservice channels.”  Finally, Hormel said that “[t]he Company is not reaffirming its previously issued GAAP earnings per share guidance range, pending completion of normal year-end financial closing procedures” and that “[a]s part of these procedures, the Company anticipates recording non-cash impairment charges, primarily related to its International segment and its snack nuts business.” 

On this news, Hormel’s stock price fell $2.15 per share, or 9.13%, to close at $21.49 per share on October 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akebia Therapeutics, Inc. - AKBA

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Akebia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 28, 2025, Akebia issued a press release “announc[ing] that after meeting with the U.S. Food and Drug Administration (FDA) it has not come to alignment on a path forward for the design of the VALOR clinical trial for the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease (CKD) not on dialysis.  As a result, Akebia does not plan to initiate VALOR and therefore does not expect to pursue a broad label for Vafseo for CKD non-dialysis dependent patients.” 

On this news, Akebia’s stock price fell $0.99 per share, or 32.04%, to close at $2.10 per share on October 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Varonis Systems, Inc. - VRNS

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Varonis Systems, Inc. (“Varonis” or the “Company”) (NASDAQ: VRNS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Varonis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 28, 2025, Varonis released its financial results for the third quarter of 2025, reporting revenue which missed consensus estimates, including a 63.9% decline in term license subscription revenues, year over year.  The Company also stated it was “reducing our full-year ARR guidance to account for the underperformance of [its] on-prem subscription business.”  On an earnings call the next day, Yakov Faitelson, the Company’s Co-Founder, Chairman, CEO & President, stated the on-premises subscription business is a “drag on total company ARR growth.”  Management also cited a number of factors which contributed to “lower renewal rate of on-prem subscription[s],” including “sales process issues.” 

On this news, Varonis’s stock price fell $30.66 per share, or 48.67%, to close at $32.34 per share on October 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Wildermuth Fund of Class Action Lawsuit and Upcoming Deadlines - WESFX; WEFCX; WEIFX

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in Class A, Class C, and/or Class I shares in the Wildermuth Fund (the “Fund”) (NASDAQ: WESFX; WEFCX; WEIFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether the Fund and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until December 29, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Class A, Class C, and/or Class I shares in the Fund during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On June 29, 2023, the Fund announced that, based on the recommendation of the Fund’s adviser, Wildermuth Advisory, LLC (“Wildermuth Advisory”), the Fund’s Board of Trustees had approved a plan of liquidation for the Fund.  At that time, Wildermuth Advisory and its owners, Daniel and Carol Wildermuth, reassured investors that there were no issues with the underlying investments held by the Fund and that the reason for its liquidation stemmed from the loss of certain tax advantages. Then, on November 1, 2023, the Wildermuths resigned from their roles as officers of the Fund.  Daniel Wildermuth further resigned as Chairman of the Board and the Fund’s agreement with Wildermuth Advisory was terminated. The Board replaced Wildermuth Advisory with BW Asset Management Ltd. (“BWAM”) as the Fund’s investment adviser.  After undertaking its own valuation of the Fund’s investments, BWAM reported that the Fund’s net asset value had, in reality, largely declined due to underperforming portfolio companies—a fact that the Fund, its Chief Financial Officer, Wildermuth Advisory, and the Wildermuths had known at all relevant times but concealed from Fund investors. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in James Hardie Industries plc of Class Action Lawsuit and Upcoming Deadlines - JHX

NEW YORK, October 29, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against James Hardie Industries plc (“James Hardie” or the “Company”) (NYSE: JHX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether James Hardie and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until December 23, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired James Hardie securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On August 19, 2025, James Hardie shocked investors by belatedly disclosing that sales in North America Fiber Cement declined by 12% due to the customer destocking first discovered by the Company and its top officers “in April through May.”  Aaron Erter, James Hardie’s Chief Executive Officer and Executive Director, explained that the results reflect a “normalization of channel inventories” that was expected to impact sales for at least the next two quarters.

On this news, James Hardie’s stock price fell $9.79 per share, or 34.44%, to close at $18.64 per share on August 20, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of America’s Car-Mart, Inc. - CRMT

NEW YORK, October 29, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  America’s Car-Mart, Inc. (“America’s Car-Mart” or the “Company”) (NASDAQ: CRMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether America’s Car-Mart and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 4, 2025, America’s Car-Mart issued a press release reporting its financial results for the first quarter of fiscal year 2026.  Among other items, America’s Car-Mart reported a first-quarter loss of $0.69 per share, compared with a net loss of $0.15 per share for the same period in the prior year.  In the press release, America’s Car-Mart President and Chief Executive Officer Doug Campbell said that “[d]uring the quarter wholesale prices rose resulting in each unit of inventory consuming more of our borrowing capacity, which places some limits on how much inventory we can carry.” 

On this news, America’s Car-Mart’s stock price fell $8.14 per share, or 18.23%, to close at $36.51 per share on September 4, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Western Alliance Bancorporation - WAL

NEW YORK, October 29, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Western Alliance Bancorporation (“Western Alliance” or the “Company”) (NYSE: WAL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Western Alliance and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 16, 2025, Western Alliance disclosed that it had initiated a lawsuit against a borrower, Cantor Group V LLC, alleging fraud related to collateral loans. 

On this news, Western Alliance’s stock price fell $8.52 per share, or 10.81%, to close at $70.32 per share on October 16, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intellia Therapeutics, Inc. - NTLA

NEW YORK, October 29, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Intellia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 27, 2025, Intellia announced that it had temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a serious liver safety event.  Specifically, Intellia halted its MAGNITUDE and MAGNITUDE-2 trials for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively, after a patient dosed with nex-z in the MAGNITUDE trial on September 30 reported Grade 4 liver transaminases and increased total bilirubin. 

On this news, Intellia’s stock price fell $10.81 per share, or 42.23%, to close at $14.79 per share on October 27, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tvardi Therapeutics, Inc. - TVRD

NEW YORK, October 29, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

 

The investigation concerns whether Tvardi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 13, 2025, Tvardi issued a press release “provid[ing] an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF).”  The press release disclosed that “[a]fter reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals.” 

On this news, Tvardi’s stock price fell $34.91 per share, or 83.92%, to close at $6.69 per share on October 13, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zions Bancorporation, N.A. - ZION

NEW YORK, October 29, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Zions Bancorporation, N.A. (“Zions” or the “Company”) (NASDAQ: ZION).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Zions and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 15, 2025, Zions announced that it would be taking a $50 million charge-off for a loan underwritten by its wholly-owned subsidiary, California Bank & Trust, in light of “apparent misrepresentations and contractual defaults by the Borrowers and Obligors and other irregularities with respect to the Loans and collateral.”  Zions further disclosed that it would be engaging counsel to coordinate an independent review of the matter. 

On this news, Zions’ stock price fell $7.10 per share, or 13.14%, to close at $46.93 per share on October 16, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexandria Real Estate Equities, Inc. - ARE

NEW YORK, October 29, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Alexandria Real Estate Equities, Inc. (“Alexandria” or the “Company”) (NYSE: ARE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Alexandria and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 27, 2025, Alexandria issued a press release reporting its financial results for the third quarter of 2025.  Among other items, Alexandria reported third quarter earnings that fell short of analyst expectations, a 5% decline in revenue, and a 7% decline in adjusted funds from operation.  Alexandria also reported a decline in its average occupancy rate from 94.8% in the prior year to 91.4%. 

On this news, Alexandria’s stock price fell $14.93 per share, or 19.17%, to close at $62.94 per share on October 28, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of F5, Inc. - FFIV

NEW YORK, November 3, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  F5, Inc. (“F5” or the “Company”) (NASDAQ: FFIV).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether F5 and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 27, 2025, F5 issued a press release announcing financial results for its fourth quarter and fiscal year 2025 ended September 30, 2025.  Among other items, F5 announced that it is “guiding to FY26 non-GAAP earnings per share in a range of $14.50 to $15.50” and “[f]or the first quarter of fiscal year 2026, . . . revenue in the range of $730 million to $780 million, with non-GAAP earnings in the range of $3.35 to $3.85 per diluted share.”  Following this weaker-than-expected guidance, various analysts cut their price targets for F5.  Ryan Koontz of Needham stated that “[w]ith revenue growth expected to slow and recently introduced headwinds including a disclosed network breach and the US Federal Government shutdown, we believe the company’s current refresh cycle is likely to delay beyond management’s expectations, damaging the company’s ability to exceed near-term expectation[.]” 

On this news, F5’s stock price fell $22.83 per share, or 7.86%, to close at $267.58 per share on October 28, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

Pomerantz Law Firm Announces the Filing of a Class Action Against DexCom, Inc. and Certain Officers – DXCM

NEW YORK, October 27, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc.  (“DexCom” or the “Company”) (NASDAQ: DXCM) and certain officers.   The class action, filed in the United States District Court for the Southern District of New York, and docketed under 25-cv-08912, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired DexCom securities between July 26, 2024 and September 17, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired DexCom securities during the Class Period, you have until December 26, 2025, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.   

[Click here for information about joining the class action]

DexCom is a medical device company primarily focused on the design, development, and commercialization of continuous glucose monitoring (“CGM”) systems for the management of diabetes and metabolic health.  The Company’s products include, inter alia, the Dexcom G6 and Dexcom G7 systems, which DexCom launched in 2018 and 2023, respectively.

The G7 is DexCom’s flagship product and, accordingly, its commercial success is of paramount importance to both investors and Defendants.  At all relevant times, Defendants consistently touted the accuracy, reliability, and functionality of the G7, as well as their purported enhancements to the device and the ramping up of its manufacturing facilities.  As of the date of this Complaint’s filing, DexCom continues to describe the G7 as its “most powerful [CGM] system” and “the most accurate CGM available.”

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) DexCom had made material design changes to the G6 and G7 unauthorized by the United States Food and Drug Administration (the “FDA”); (ii) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, Defendants’ purported enhancements to the G7, as well as the device’s reliability, accuracy, and functionality, were overstated; (iv) Defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (v) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (vi) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

On March 7, 2025, DexCom disclosed in an United States Securities and Exchange Commission filing that, three days earlier, it had received a warning letter (the “Warning Letter”) from the FDA related to concerns about manufacturing processes and quality management systems at certain of the Company’s facilities.

On this news, DexCom’s stock price fell $7.12 per share, or 9.15%, to close at $70.72 per share on March 10, 2025, the next trading day.

On March 25, 2025, the FDA published the Warning Letter on its website, revealing that DexCom had “adulterated” its G6 and G7 products by “modif[ying] the G6 and G7 sensors” without prior regulatory approval, thereby subjecting the devices to “larger inaccuracies” that “cause higher risks for users who rely on the sensors to dose insulin or make other diabetes treatment decisions.”

On this news, DexCom’s stock price fell $3.19 per share, or 4.24%, over the following two trading sessions, to close at $72.13 per share on March 26, 2025.

On September 8, 2025, equity research firm Oppenheimer issued a note downgrading DexCom’s rating to “perform” from “outperform.”  Oppenheimer also removed its $102.00 price target on the Company’s stock.  Oppenheimer cited, inter alia, patient concern with the G7’s poor accuracy, failed sensor insertions, abrupt stoppages, and other issues, noting that “field checks point to rising concerns about G7 accuracy/performance.”

On this news, DexCom’s stock price fell $2.51 per share, or 3.12%, to close at $78.00 per share on September 8, 2025.

Then, on September 18, 2025, Hunterbrook published a report addressing DexCom, entitled “Dexcom’s Fatal Flaws”.  The Hunterbrook report revealed, inter alia, that issues and health risks posed by adulterated G7 devices were more severe and widespread than previously disclosed, citing FDA documents it had procured via a Freedom of Information Act request, as well as various comments from doctors, patients and their families, and former DexCom employees.  Specifically, the Hunterbrook report found that “G7 users have been hospitalized and died” following inaccurate glucose readings, linking these deadly incidents to adulterated G7 devices and Defendants’ willingness to cut corners to meet margins.

On this news, DexCom’s stock price fell $8.99 per share, or 11.76%, over the following two trading sessions, to close at $67.45 per share on September 19, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcome.